| Name | Title | Contact Details |
|---|
Wexford Health Sources, Inc., a correctional health care company, provides health care programs for the corrections departments and/or human services agencies, as well as programs for jail clients in the United States. It offers medical services to implement and maintain a correctional health care delivery system that includes onsite care, offsite care, vision and hearing, infection control, durable medical equipment, medical recordkeeping, hospice and end-of-life, and re-entry and recidivism programs; laboratory, X-ray, and other diagnostic services; physical, occupational, and speech therapy services; and mobile surgery units, chemotherapy, specialized onsite diagnostic services, etc. The company also manages a range of behavioral health programs at various acuity levels, including outpatient, crisis stabilization and management, and acute psychiatric inpatient care. In addition, it offers mental health programs; detoxification program for inmates who are chemically dependent, intoxicated, or undergoing withdrawal upon entering a facility; substance abuse counseling services, including assessment and referral; individual and group counseling; therapeutic communities; and other treatment interventions. Further, the company provides psychologically based sex offender treatment program that includes assessment, treatment, and discharge planning; pharmacy and pharmaceutical consulting services, including the prescribing, dispensing, delivery, administration, management, and disposal of prescription and non-prescription medications; and rehabilitation, utilization management, and claims processing services to state, regional, and local clients. It manages health care programs for correctional facilities and other types of institutions, including prisons, juvenile detention centers, substance abuse facilities, mental health units, and sex offender treatment centers. Wexford Health Sources, Inc. was incorporated in 1992 and is based in Pittsburgh, Pennsylvania.
Intrigma is a leader in medical scheduling solutions that deliver bottom-line impact to medical groups, hospitals and hospital systems.
Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.
RCM of Washington is a Washington, DC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Satori Labs is a Scotts Valley, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.